Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Repligen Corporation Common Stock — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.64 (market cap $8.54B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 51 Days and Repligen Corporation Common Stock for 0 Days on average.
| QYLD | RGEN | |
|---|---|---|
Market Cap | $8.54B | $11.14B |
Volume | 2,383,712 | 1,259,263 |
Sector | Income / Options Overlay | Health |
52-Week High | $18.69 | $194.57 |
52-Week Low | $16.70 | $102.87 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF's technical outlook is bullish based on moving averages, but oscillators signal caution with RSI levels above 75 indicating overbought conditions. Recent news highlights its high monthly dividend yield but raises concerns about long-term capital erosion and capped upside due to its covered call strategy, with distributions consistently at $0.18 per share.
The outlook for QYLD is mixed; it offers attractive income with a high yield, appealing for investors seeking monthly cash flow. However, risks include limited growth potential, declining option premiums, and potential tax reclassification of dividends. Analyst sentiment is divided, with some upgrades citing yield attractiveness but others warning of principal erosion over time.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
